Retargeted Clostridial Neurotoxins as Novel Agents for Treating Chronic Diseases

被引：7

作者：

Yeh, Felix L. ^{[1
]}

Zhu, Yiming ^{[2
]}

Tepp, William H. ^{[3
]}

Johnson, Eric A. ^{[3
]}

Bertics, Paul J. ^{[2
]}

Chapman, Edwin R. ^{[1
]}

机构：

[1] Univ Wisconsin, Dept Neurosci, Howard Hughes Med Inst, Madison, WI 53706 USA

[2] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA

[3] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA

来源：

BIOCHEMISTRY | 2011年 / 50卷 / 48期

关键词：

TUMOR-NECROSIS-FACTOR; NEUROTRANSMITTER RELEASE; IN-VITRO; BOTULINUM; EXPRESSION; CYTOKINES; STRATEGY; PROTEIN; TARGET; TOXIN;

D O I：

10.1021/bi201490t

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Botulinum neurotoxin (BoNT) A and B are used to treat neuropathic disorders; if retargeted, these agents could be used to treat medical conditions that involve secretion from nonneuronal cells. Here, we report novel strategies for successfully retargeting BoNTs, and also tetanus neurotoxin (TeNT), to primary human blood monocyte-derived macrophages where BoNT/B inhibited the release of tumor necrosis factor-alpha, a cytokine that plays a key role in inflammation. Furthermore, mice treated with retargeted BoNT/B exhibited a significant reduction in macrophage (M Phi) recruitment, indicating that these toxins can be used to treat chronic inflammation.

引用

页码：10419 / 10421

页数：3

共 50 条

[1] Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Chen, Sheng
CURRENT PROTEIN & PEPTIDE SCIENCE, 2014, 15 (05) : 490 - 503
[2] Neurodegenerative diseases:: Neurotoxins as sufficient etiologic agents?
Shaw, Christopher A.
Hoeglinger, Guenter U.
NEUROMOLECULAR MEDICINE, 2008, 10 (01) : 1 - 9
[3] Neurodegenerative Diseases: Neurotoxins as Sufficient Etiologic Agents?
Christopher A. Shaw
Günter U. Höglinger
NeuroMolecular Medicine, 2008, 10 : 1 - 9
[4] Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid -: Novel insights into the receptor for clostridial neurotoxins
Tsukamoto, K
Kohda, T
Mukamoto, M
Takeuchi, K
Ihara, H
Saito, M
Kozaki, S
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (42) : 35164 - 35171
[5] Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics
Foster, KA
Adams, EJ
Durose, L
Cruttwell, CJ
Marks, E
Shone, CC
Chaddock, JA
Cox, CL
Heaton, C
Sutton, JM
Wayne, J
Alexander, FCG
Rogers, DF
NEUROTOXICITY RESEARCH, 2006, 9 (2-3) : 101 - 107
[6] Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics
Keith A. Foster
Emily J. Adams
Lyndsey Durose
Caroline J. Cruttwell
Elizabeth Marks
Clifford C. Shone
John A. Chaddock
Clare L. Cox
Charlotte Heaton
J. Mark Sutton
Jonathan Wayne
Frances C. G. Alexander
Duncan F. Rogers
Neurotoxicity Research, 2006, 9 : 101 - 107
[7] Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic PainCurrent Status and Future Prospects
Andy Pickett
BioDrugs, 2010, 24 : 173 - 182
[8] Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain Current Status and Future Prospects
Pickett, Andy
BIODRUGS, 2010, 24 (03) : 173 - 182
[9] Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases
Mongelli, Alessia
Atlante, Sandra
Barbi, Veronica
Bachetti, Tiziana
Martelli, Fabio
Farsetti, Antonella
Gaetano, Carlo
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) : 1 - 21
[10] Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis
Wu, Jijiao
Wen, Lin
Liu, Xiaolian
Li, Qiuxia
Sun, Zihao
Liang, Chuipeng
Xie, Fan
Li, Xiaofang
PHYTOTHERAPY RESEARCH, 2024,

← 1 2 3 4 5 →